1-3 of 3
Huai-Xiang Hao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Free
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J. Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J. Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J. Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2368–2380.
https://doi.org/10.1158/1535-7163.MCT-19-0170
Published: 02 December 2019
View article titled, Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Open the PDF for Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Free
Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai-Xiang Hao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (7): 1323–1334.
https://doi.org/10.1158/1535-7163.MCT-18-0852
Published: 01 July 2019
View article titled, SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Open the PDF for SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Free
Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (5): 1224–1235.
https://doi.org/10.1158/1535-7163.MCT-14-0768
Published: 05 May 2015
View article titled, Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Open the PDF for Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus in another window
Includes: Supplementary data